All In Biotech

Investigational drug · Phase 2

SUN-627

Also called: NEU-627, N-004850

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Primary Progressive Multiple Sclerosis, Primary Progressive MS, Primary Progressive Multiple Sclerosis (PPMS).

Phase 2

Last checked: Nov 19, 2026Latest source record: Oct 30, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

1

1 still active

All registered trials

1

Any phase or sponsor naming "SUN-627"

First trial start

2026

Oct 2026

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "SUN-627", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Primary Progressive Multiple Sclerosis
  • Primary Progressive MS
  • Primary Progressive Multiple Sclerosis (PPMS)
  • Secondary Progressive MS (SPMS)
  • Secondary Progressive Multiple Sclerosis (SPMS)
  • Secondary Progressive MS
  • Non-Active SPMS
  • Non-Active Secondary Progressive Multiple Sclerosis
  • Secondary Progressive Multiple Sclerosis With Inflammatory Disease Activity

Approved drugs for the same conditions: Multiple sclerosis · Neurology

Largest trials

Live from ClinicalTrials.gov: studies naming "SUN-627" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 0 on PubMed

No PubMed records name it yet, which is common for early code-named drugs.

Also in development for Primary Progressive Multiple Sclerosis

  • TolebrutinibSAR442168Phase 33 trials

    Sanofi · Relapsing Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Progressive Relapsing Multiple Sclerosis

  • C-CAR168Phase 22 trials

    AbelZeta Inc. · Lupus Nephritis (LN), Systemic Lupus Erythematosus (SLE), Autoimmune Diseases

  • TRX319Phase 21 trial

    Tr1X, Inc. · Primary Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis (SPMS), Multiple Sclerosis

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.